Parkinson's Disease Research
Parkinson's disease (PD) is a degenerative disease of the central nervous system that often impairs motor skills, speech, and other functions. Symptoms of the disease include resting tremor, bradykinesia and rigidity. The primary symptoms are the result of decreased stimulation of the motor cortex by the basal ganglia, normally caused by the insufficient formation and action of dopamine, which is produced in the dopaminergic neurons of the brain. Symptoms of the disease appear once 50-80% of dopamine neurons have died. Parkinson's disease is both chronic and progressive.
Parkinson's Disease Research Products Targets
- Adenosine A2B Receptor (7)
- Adenosine A2A Receptor (11)
- Caspase (9)
- Bcl-2 Family (13)
- Voltage-gated Calcium Channel (CaV) (38)
- GABAB Receptor (28)
- Others (23)
- Cyclooxygenase (24)
- D4 Receptor (12)
- STIM-Orai Channel (4)
- Ryanodine Receptor (6)
- Hsp90 (10)
- Hsp70 (4)
- 5-HT7 Receptor (11)
- 5-HT6 Receptor (14)
- 5-ht5 Receptor (2)
- 5-HT4 Receptor (17)
- Glutamate (Metabotropic) Group III Receptor (26)
- Glutamate (Metabotropic) Group II Receptor (33)
- Glutamate (Metabotropic) Group I Receptor (54)
- AMPA Receptor (45)
- GABAA-ρ Receptor (8)
- GABAA Receptor (66)
- Nicotinic (α7) Receptor (25)
- Nicotinic (α4β2) Receptor (14)
- D3 Receptor (12)
- LRRK2 (4)
- Catechol O-Methyltransferase (3)
- Vesicular Monoamine Transporter (4)
- NMDA Receptor (87)
- Kainate Receptor (22)
- IP3 Receptor (2)
- D2 Receptor (14)
- D1 and D5 Receptor (16)
- Trk Receptor (13)
- Trace Amine 1 Receptor (2)
- Adenosine A3 Receptor (8)
- Adenosine A1 Receptor (12)
- Monoamine Oxidase (10)
- M5 Receptor (2)
- M4 Receptor (3)
- M3 Receptor (4)
- M2 Receptor (5)
- M1 Receptor (8)
- Adrenergic α2 Receptor (33)
- Adrenergic α1 Receptor (22)
- Adrenergic β3 Receptor (12)
- Adrenergic β2 Receptor (6)
- Adrenergic β1 Receptor (7)
- Protein Arginine Methyltransferase (2)
Products for Parkinson's Disease Research - Page 64
- Cat.No. Product Name Information/Activity
-
BCC6730
Synthalin sulfate
182285-12-7
-
BCC6122
TCN 201
852918-02-6
-
BCC6123
TCN 213
556803-08-8
-
BCC6111
TCN 237 dihydrochloride
NMDA-IN-1 is a potent and NR2B-selective NMDA antagonist with Ki of 0.85 nM; NR2B Ca2+ influx IC50 is 9.7 nM; no activities on NR2A, NR2C, NR2D, hERG-channel and α1-adrenergic receptor.
-
BCC7482
TCS 46b
302799-86-6
-
BCC6984
CCMQ
132623-44-0
-
BCC7862
CIQ
CIQ is a subunit-selective potentiator of NMDA receptors containing the NR2C or NR2D subunit.
-
BCC2946
H-Gly-OH
Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors.
-
BCC5888
MNI-caged-NMDA
1227675-52-6
-
BCC7292
N20C hydrochloride
1177583-87-7


